Trulieve Posts Q2 Net Loss Of $407 Million Due To Asset Impairments
The stateside cannabis sector continues to follow the path of the Canadian cannabis sector, with Trulieve Cannabis (CSE: TRUL) this morning reporting a massive net loss for the second quarter of 2023 as a result of goodwill impairments.
The company saw a net loss of $406.9 million for the second quarter, driven in large part by the impairment of goodwill to the tune of $307.6 million. The impairment was triggered by the recent share price performance of the company, rather than as a result of the operations themselves. Excluding discontinued operations, disposals, impairments, and non-recurring charges, Trulieve reported an “adjusted net loss” of $15 million.
Revenue declined on a quarter over quarter basis for the multi state operator, dropping from $289 million to $282 million, with the company noting that price compression is becoming a factor in its revenue growth.
On a year over year basis, revenue declined 10% from $314 million. This decline comes as the company has exited its California retail assets and commenced a wind down of its operations in Massachusetts in an effort to preserve cash.
“We are on track to exit this year as a leaner, stronger organization, ready to meet the opportunities ahead,” commented CEO Kim Rivers.
Gross profit declined from $150 million to $142 million sequentially, while margins dropped two percentage points to 50%.
READ: Trulieve Cannabis Sees CFO Quit After Just Ten Days On The Job
SG&A expenses however also fell, dropping from $102 million to $96 million, before factoring in the goodwill impairment.
Adjusted EBITDA for the quarter came in at $79 million, an improvement over the $78 million figure reported in the first quarter, while cash flow from operations excluding tax payments rose to $98 million year to date. Despite this, the firms cash position declined from $195 million to $160 million over the course of the second quarter.
Total current assets declined from $574.2 million to $474.8 million during the quarter, while total current liabilities increased from $188.3 million to $240.6 million.
Trulieve Cannabis last traded at $5.69 on the CSE.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
